Ophthalmic drug development

We help biotechs decide whether a drug belongs in the eye, and help CROs build the services to test it.

For biotechs

Find out whether your lead candidate has a credible route into the eye, before you commit serious capital.

A good chance of success 71.6%vs 52.0% Ophthalmic drugs move from Phase I to Phase II more often than in any other disease area. We tell you whether yours belongs in the eye before you commit serious capital.
More investable 2.9xvs 1.7x A drug that treats more than one indication returns 2.9x from preclinical to approval, against 1.7x for one alone. The evidence plan and the patent position are what let you claim the second one and show the risk coming down.
Attractive to big pharma US$1.3Bupfront Paid by Merck for EyeBio in 2024, with its lead candidate still in early clinical trials. Large pharma now sources 55% of new drugs from outside its own laboratories, and buys once early clinical risk is retired.
Find out more →

For CROs

Three new service lines, built on your own infrastructure. Each one pays back in a different way.

Ophthalmic services 10.2%a year Growth in ophthalmology CRO work, ahead of preclinical services generally. Few laboratories can run an ocular study, so this is work you decline today.
Advanced omics 8.9%a year Growth in CRO and service-provider demand for transcriptome sequencing, the fastest-growing buyer segment. Bulk RNA-seq is the mainstay. We handle the analysis, so you sell the readout without building a bioinformatics team.
Automated analysis 45%of the time back Roughly 45% of working time goes on preparing data rather than analysing it. Agents run the analysis on your existing systems and assemble the report; your scientists keep the sign-off.
Find out more →
Dr. Adrian Cioanca

Founder and team

Managing Director & Founder

Dr. Adrian Cioanca

Retinal scientist, biotech co-founder and strategy consultant.

Passionate about translation, and impatient to see more leads reach the ophthalmic market. My career gave me the chance to do the research, commercialise it, and help biotechs of every size bring new candidates into the eye.

Where to start

Read how we work with whichever side you are on. Each page sets out the tracks, what you get at the end of each one, what it costs and where the evidence comes from.